SCHEMBL5367195

SCHEMBL5367195

Cc1ccc(C=C2C(=O)Nc3ccc(CN)cc32)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.57
EGFR P00533 2/20 0.47
KMT2A Q03164 9/20 0.47
ALDH1A1 P00352 7/20 0.47
MAPT P10636 7/20 0.47
HPGD P15428 5/20 0.47
MEN1 O00255 4/20 0.47
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RET P07949 4/20 0.41
FLT3 P36888 2/20 0.41
ALK Q9UM73 1/20 0.41
POLB P06746 4/20 0.41
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
TNFRSF1A P19438 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359077 0.88 EGFR (0.47) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL5362113 0.86 KMT2A (0.47) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL14519107 0.83 FGFR1 (0.48) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL6001533 0.81 LRRK2 (0.58) EGFRRETPDGFRB
SCHEMBL6001532 0.81 LRRK2 (0.58) EGFRRETPDGFRB
SCHEMBL5361627 0.80 SYK (0.58) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL5364974 0.79 PDPK1 (0.46) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL14519109 0.78 TLK2 (0.57) PDPK1KMT2AMEN1KDRPDGFRB
SCHEMBL5728059 0.78 EGFR (0.69) PDPK1EGFRKMT2AALDH1A1MAPT
SCHEMBL5728062 0.78 EGFR (0.69) PDPK1EGFRKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885EGFR 286/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.